Kornimate/medical-research-clean huggingface dataset:
animal-assisted therapy in adolescents with eating disorders

Conditions: Eating Disorders in Adolescence; Eating Disorders; Anorexia Nervosa/Bulimia

Summary: this study aims to improve eating disorders symptomatology, mental, psychosocial and physical health, quality of life, strength and body composition of adolescents with eating disorders by the development of a dog-assisted therapy program. the current research will involve thirty-two patients distributed equally in a control and an experimental group. the intervention group will participate once a week in a dog-assisted therapy of seven weeks. moreover, all the included patients will participate in an assessment session before and after the intervention to compare the effects of the dog-assisted therapy within and between groups in anxiety, depression, character, behavior, eating disorder evolution, health-related quality of life, treatment satisfaction, strength and body composition. based on previous studies on different populations, it is expected that, compared to the control group, the experimental group may experience a potential reduction in anxiety, depression and symptoms, while improving quality of life, strength, body composition and behavior.

animal-assisted therapies (aat) have proved to increase self-esteem, social capacity and impulse control while reducing anxiety and depression. thus, aat could be an innovative and effective therapy to improve the mental, social and physical health of adolescents with eating disorders. based on previous studies on different populations, it is expected that, compared to the control group, the experimental group may experience a potential reduction in anxiety, depression and symptoms, while improving quality of life, strength, body composition and behavior. thirty-two adolescents, younger than 18 years and diagnosed with eating disorders from the university hospital niño jesus will participate in this study. the informed consent must be signed to be included in the study. the intervention will consist of 7 weeks conducted once a week (50 minutes each session). it will include three parts: 1) a welcome part aimed to get in touch with the dog, 2) a main part, where participants will be taught basic notions about dog training and then try to train the dogs. in this part, the patients will perform different activities and exercises with the dog. 3) a closing part to say goodbye to the dogs.

Eligibility criteria:
inclusion criteria: * adolescents in the psychiatry and psychology service of the niño jesús university hospital * patients diagnosed with eating disorders * adolescents with the willingness to participate and availability to assist * having read and signed the written informed consent. exclusion criteria: * patients with dog-allergy or dog phobia * adolescents with a history of impulsive animal aggression

Keywords: dog-assisted intervention eating disorder symptom depression anxiety adolescent behavior and character health-related quality of life strength body composition treatment satisfaction
bolus versus continuous remimazolam for anesthetic induction

Conditions: Hypotension on Induction

Summary: remimazolam is a newly introduced intravenous anesthetic, with rapid onset and offset. although it is known to cause less hemodynamic instability, the incidence hypotension is the one of the most frequent adverse events with its use. for anesthetic induction, remimazolam can be used either as bolus dose or as continuous infusion. this study is aimed to investigate the incidence of hypotension after anesthetic induction with bolus (0.14-0.33 mg/kg) or continuous (12 mg/kg/hr) remimazolam administration.


Eligibility criteria:
inclusion criteria: * scheduled for elective surgery under general anesthesia * adult patient (over 19 years old) * american society of anesthesiology physical status i-iii exclusion criteria: * arrythmia * liver dysfunction * kidney dysfunction * uncontrolled hypertension * uncontrolled diabetes mellitus * allergic to benzodiazepines * heart failure * drug intoxication * alcohol intoxication
individualized pharmaceutical-care for inpatients with cancer pain

Conditions: Cancer Pain

Summary: the purpose of the study is to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant inpatients

this study is a prospective multicenter randomized controlled study to investigate the impact of pharmaceutical care on cancer pain treatment for opioid-tolerant inpatients.

Eligibility criteria:
inclusion criteria: * patients aged 18 years or older; * histologically confirmed solid tumor; * diagnosed chronic cancer pain; * opioid-tolerant patients; * overall survival is expected to be over 3 months; * karnofsky performance score≥50; * willing and able to comply with the protocol exclusion criteria: * current pregnancy or breastfeeding; * patients diagnosed with non-cancer pain; * patients treated with patient-controlled analgesia; * patients with pathological fracture, gastrointestinal obstruction, severe infection, non-opioid related intractable constipation; * patients with mental disorder; * creatinine clearance rate \<15ml/min; * alt or ast ≥ 10 fold of upper limit of normal value

Keywords: cancer pain pharmaceutical care
maximum tolerated dose, safety and pharmacologic study of trf in women with breast cancer

Conditions: Breast Cancer Female

Summary: phase ib: maximum tolerated dose, safety and pharmacologic study of trf in women with breast cancer is aimed to determine the highest, safest and tolerable dose of tocotrienol-rich fraction (maximal tolerated dose: mtd) that can be used in women with breast cancer.

3+3 step up design method will be used in this study.

Eligibility criteria:
inclusion criteria: * patients with operable breast cancer * life expectancy of at least 3 months * adequate organ function * no allergy to vitamin e and trf * provides consent to participate in trial and adhere to the study protocol exclusion criteria: * receiving concomitant chemotherapy, radiotherapy, hormonal, immune therapy or other investigational drugs * uncontrolled concurrent illness * pregnant / breast feeding women * patients who are unable or unwilling to take tocotrienols, herbal remedies, or non-prescription medications

Keywords: mtd trf pharmacology
low-dose acetylsalicylic acid in treating patients with stage i-iii non-small cell lung cancer

Conditions: Adenocarcinoma of the Lung; Recurrent Non-small Cell Lung Cancer; Stage IA Non-small Cell Lung Cancer; Stage IB Non-small Cell Lung Cancer; Stage IIA Non-small Cell Lung Cancer; Stage IIB Non-small Cell Lung Cancer; Stage IIIA Non-small Cell Lung Cancer; Stage IIIB Non-small Cell Lung Cancer

Summary: this pilot clinical trial studies low-dose acetylsalicylic acid in treating patients with stage i-iii non-small cell lung cancer. studying samples of urine and blood from patients with cancer in the laboratory may help doctors learn more about changes in biomarkers that occur during treatment with acetylsalicylic acid

primary objectives: i. to determine whether asa (acetylsalicylic acid) 325 mg inhibits prostaglandin e2 (pge2) biosynthesis in patients with early stage non-small cell lung cancer (nsclc). cyclooxygenase (cox) catalytic activity will be determined by measuring the metabolite of pge2, 11alpha-hydroxy-9,12-dioxo-2,3,4,5-tetranor-prostane-1,20 dioic acid (pge-m) in urine pre- and post-asa 325 mg as a surrogate of systemic pge2 biosynthesis. secondary objectives: i. to determine whether cox-2 protein has a slow turnover in adenocarcinoma of the lung. cox turnover will be determined by measuring urinary pge-m levels daily for 7 days after discontinuing asa 325 mg. cox-2 and prostaglandin expression will also be measured in tumor samples of patients taken at the time of surgery. outline: patients receive acetylsalicylic acid orally (po) for 7 days and urine is collected for 7 days post therapy.

Eligibility criteria:
inclusion criteria: * have confirmed (stage iiib-iv) or recurrent non-small cell lung cancer, adenocarcinoma histology * understand and voluntarily sign an informed consent document prior to any study related assessments or procedures are conducted * anticipated that they will complete all study procedures * ability to swallow pills * no aspirin in the last 7 days exclusion criteria: * know allergy to aspirin or other nonsteroidal anti-inflammatory drugs * history of allergic reaction to aspirin or other non-steroidal anti-inflammatory drugs, including ibuprofen * any other concomitant serious illness or organ system dysfunction which in the opinion of the investigator would either compromise patient safety
doppler at the diagnosis in predicting perinatal outcomes in early and late-onset fetal growth restriction

Conditions: Fetal Growth Retardation

Summary: when a fgr is diagnose, the challenge in his monitoring is to assess the benefit-risk balance between continuing the pregnancy in order to limit complications related to prematurity and birth in order to minimize any risk of fetal death in utero. by able to know the characteristics of fetal deteriorations and its relationship with fetal and neonatal outcomes could be a thankful help in this decision. the placental insufficiency is by far the most common cause of fgr (32)(miller 2008). this effect can be documented thanks to ultrasound examinations to study fetal growth and doppler of umbilical arteries for the placenta, the middle cerebral artery for the brain perfusion and the ductus venosus for the cardiac effects of placental dysfunction. the apparition of doppler abnormalities suggests a deterioration of the disease and leads to several changes in clinical fgr management. nevertheless, at this time, very few studies allow us to predict the time util the degradation and their impact on perinatal outcomes. the primary aim of this study was to evaluate the performance of the doppler at the time of diagnosis in predicting the outcome of pregnancies. the secondary aim was to evaluate the performance of doppler performed at any time during pregnancy and studied independently in predicting outcome of pregnancies


Eligibility criteria:
inclusion criteria: * fetal growth restriction of antenatal diagnosis exclusion criteria: * twin pregnancies, non-isolated iugr, post-natal diagnosis of fgr and incomplete records

Keywords: fetal growth retardation, doppler, perinatale outcome
effects of frequent decision making among patients with serious illnesses

Conditions: Chemotherapy

Summary: decision making capacity fatigues after repeated decisions similar to skeletal muscle. the result is decision fatigue, in which subsequent decisions are altered toward the status quo. patients are at risk for decision fatigue yet it has not been studied. the investigator proposes a randomized study in the outpatient setting in patients at high risk for needing to make complex decisions, in an effort to determine the impact of decision fatigue on participant self-control and subsequent choices.

just as skeletal muscle fatigues after repeated use, decision-making capacity fatigues when repeated choices are made. this phenomenon, in which people experience diminished concentration and willpower after repeated decision-making, is termed decision fatigue. (1) people experiencing decision fatigue are more likely to bias subsequent choices toward the status quo. by choosing the status quo, the decision-maker reserves the option to make an alternate choice at a later time, thereby preserving possibilities. patients and their surrogates often make complex medical decisions for which they may have little experience. although clearly at high risk, decision fatigue has not been studied this population. to elucidate these questions, we propose a four arm study of patients in a population at high risk for making complex decisions. participants will be randomly assigned to varied levels of decision making effort to assess for the development of resultant decision fatigue and whether it alters subsequent decisions.

Eligibility criteria:
inclusion criteria: * aplastic anemia, multiple myeloma, myelodysplastic syndrome, acute myeloid leukemia, stage iiib or iv lung cancer, mesothelioma and/or stage iiib or iv gastrointestinal cancer (pancreatic, biliary, esophageal, gastric, hepatocellular, colon), stage iv melanoma * all participants must be over the age 18 * all participants must be fluent in english exclusion criteria: * any medical condition known to alter stroop performance; i.e. significant visual impairment, blind or colorblind, sedating medications during appointment, history of cerebrovascular accident, transient ischemic attack (tia), seizure disorder, dementia or traumatic head injury with loss of consciousness * patients will also be ineligible if they are illiterate * patients will be ineligible if they have either tracheostomy or are currently on hemodialysis as these would significantly alter responses to the hypothetical medical scenarios/decisions

Keywords: decision fatigue
a study of cm310 in patients with moderate-to-severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this is a multi-center, randomized, double blind, placebo-controlled phase 3 study to evaluate the efficacy, safety, pk, pd and immunogenicity of cm310 in patients with moderate-to-severe atopic dermatitis.

the study consists of an up-to-4-week screening period, a 16-week double-blind treatment period, a 36-week maintenance treatment period, and a 8-week safety follow-up period.

Eligibility criteria:
inclusion criteria: * diagnosed with ad for at least 12 months before screening, with below requirements: 1) easi score ≥16 at screening and baseline; 2) iga score ≥3 at screening and baseline; 3) ≥10% bsa of ad involvement at screening and baseline; 4) pruritus nrs average score ≥3 at baseline. exclusion criteria: * not enough washing-out period for previous therapy. * concurrent disease/status which may potentially affect the efficacy/safety judgement. * organ dysfunction. * pregnancy. * other.
decentralized trial in atrial fibrillation patients

Conditions: Atrial Fibrillation

Summary: the purpose of this study is to validate an approach to decentralize, or virtualize, the clinical trial experience for enrolled subjects, through the coordinated use of multiple digital health and telehealth technologies. the study aims to validate the feasibility, acceptability and best practices of coordinating/integrating several individual digital health technologies to achieve execution of high compliance, cost-efficient, and scientifically sound clinical trials.


Eligibility criteria:
inclusion criteria: * diagnosis of atrial fibrillation documented (health record diagnosis or ekg) within the past year and taking an oral anticoagulant (oac) medication for stroke prevention * uses a smart phone daily and is willing to use apps and home devices for the study * agreeable to use a televisit method to conduct all study visits from trial team exclusion criteria: * active angina, stable or unstable, requiring urgent cardiovascular functional risk stratification (stress testing or catheterization) or intervention. or has congestive heart failure that is not compensated or in which the subject is not euvolemic, as determined by the treating md * individual has a condition the investigator believes would interfere with his or her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results or put the person at undue risk. * does not speak english
application of rotem technology in aortic surgery

Conditions: Aortic Surgery; Coagulation Management

Summary: comparison of the diagnostic capabilities of rotational thromboelastometry (rotem) and standard coagulogram in the detection of disorder and correction of the hemostasis system in the perioperative period in patients who underwent surgical intervention on the aorta under cardiopulmonary bypass and or circulatory arrest.

the patient is monitored in the intensive care unit according to the following scheme: rotem (natem, intem, extem, fibtem; with high clotting time (ct) values in intem - heptem is done) and a coagulogram (activated coagulation time (act), activated partial thromboplastin time (aptt), prothrombin time (pt), thrombin time (tt), fibrinogen, antithrombin iii, platelet aggregation) are done on admission and after 6 hours - with a smooth course of the perioperative period. if it is necessary or the development of disorders in the form of bleeding or thrombosis that require correction, rotem and a coagulogram are done, treatment is carried out, and after elimination of the causes, rotem and a coagulogram are examined in dynamics to assess the effectiveness of the therapy.

Eligibility criteria:
inclusion criteria: * age from 18 to 80 years. * patients after surgical interventions on the aorta with cardiopulmonary bypass and/or circulatory arrest (operations on the ascending aorta, aortic arch and thoracoabdominal aorta). exclusion criteria: * patients with other cardiac surgery, including isolated endovascular interventions on the aorta.

Keywords: rotem coagulation tests coagulation disorders aortic surgery
ultrasonographic and comfort comparison of sitting fetal cross-legged position with lateral decubitus fetal position

Conditions: Anesthesia, Conduction

Summary: a prosperous neuraxial anesthesia positioning ensures a raised chance of successful needle placement. the primary aim is to compare "sitting cross-legged fetal position -scf" with "lateral decubitus fetal position-ldf" anatomically via sonography. secondary aim is to compare their comfort.

fifty participants were included to this prospective, randomized, consecutive controlled clinical study. six parameters were evaluated in each position; subcutaneous tissue (st), skin to spinous process (s-sp), transverse diameters of bilateral paraspinal muscles (left paraspinal muscle \[lpm\] and right paraspinal muscle \[rpm\]), interspinous gap opening (isgo), mean of bilateral paraspinal muscles (mpm). the change of every measurement recorded via ultrasonography (usg) according to the positioning techniques were also calculated. the calculations are explained briefly in primary outcomes (including the change of scf-ldf in st, s-sp, lpm, rpm, mpm, isgo). stretcher comfort (sc), position comfort (pc), lumbar comfort (lc), and abdominal comfort (ac) were evaluated by the participants with the 7-point numerical rating scale (nrs).

Eligibility criteria:
inclusion criteria: * healthy and adult volunteers, * must be able to do the sitting cross-legged fetal position ( scf ), * must be able to do the lateral decubitus fetal position (ldf). exclusion criteria: * lumbar hernia, * scoliosis, * history of spine surgery, * history of trauma, * history of lower back pain, * arthropathy {especially pelvic or knee problems}, * could not be able to do one or both of the two neuraxial position techniques.

Keywords: neuraxial anesthesia positioning technique sitting cross-legged fetal position lateral decubitus fetal position ultrasonography
effect of aqueous extract of garlic and nystatin mouthwash in denture stomatitis

Conditions: Denture Stomatitis

Summary: the aim of the present study was to compare the effect of aqueous extract of garlic with nystatin mouthwash in denture stomatitis.

denture stomatitis is the most common form of chronic oral candidiasis manifested as chronic inflammation of the mucous membrane t supporting the movable prosthesis that may have a local or systemic nature. this inflammation is presented as mucous erythema and occasionally with pain and burning. the standard treatment for denture stomatitis is administration of nystatin which is accompanied with complications such as bitter taste as well as the high number of drug application that result in reduced tendency of patients in using this medication hence, efforts are continuously being made to substitute other types of therapies for this condition.

Eligibility criteria:
inclusion criteria: * 40 years of age and older * confirm of denture stomatitis by the oral medicine specialists exclusion criteria: * patients with a history of using anti-fungal drugs, antibiotics, and corticosteroid within the previous month * allergy to garlic and nystatin mouthwash * immunodeficiency * uncontrolled diabetes * those with garlic rich diet * inability in using mouthwash * loose and discolored dentures * psychologic disorder and alzheimer

Keywords: denture stomatitis nystatin garlic
effect of symbicort on sleep quality in patients with emphysema

Conditions: Emphysema; Poor Sleep Quality

Summary: this study will look at the effects of the drug symbicort on sleep quality. symbicort is an inhaled medication that contains 2 drugs. one is a medication that opens up the airways (formoterol). the other is a steroid to decrease airway inflammation (budesonide). symbicort is not an experimental medication. it is approved by the food and drug administration for use in patients with emphysema. patients with severe emphysema commonly sleep poorly. the cause of poor sleep in these patients is unknown. symbicort may improve sleep quality by opening the airways and reducing lung inflammation. it is not known for sure if these effects actually improve sleep and quality of life. it is hoped that this study will answer this question.


Eligibility criteria:
inclusion criteria: * moderate to severe emphysema (gold stages 2 and 3) exclusion criteria: * use of supplemental oxygen, * a recent copd exacerbation within the past 4 weeks. * a previous diagnosis of obstructive sleep apnea * a known urinary outflow obstruction, * glaucoma * history of an allergic reaction to one of the study medications.

Keywords: emphysema copd sleep
efficacy of ciclesonide versus fluticasone propionate in patients with mild to moderate asthma (12 to 75 y) (by9010/m1-142)

Conditions: Asthma

Summary: the aim of the study is to compare the efficacy of ciclesonide versus fluticasone propionate on lung function, time to first asthma exacerbation, asthma symptoms, use of rescue medication, and quality of life in patients with mild to moderate asthma. ciclesonide will be inhaled at one dose level once daily; fluticasone propionate will be inhaled at one dose level twice daily. the study duration consists of a baseline period (2 to 4 weeks) and a treatment period (24 weeks). the study will provide further data on safety and tolerability of ciclesonide.


Eligibility criteria:
main inclusion criteria: * outpatients * written informed consent * history of bronchial asthma for at least 6 months * good health with the exception of asthma * treated with inhaled steroids with a maximum daily constant dosage of 250 mcg fluticasone propionate or equivalent * fev1 80 - 105% of predicted main exclusion criteria: * concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids * copd (i.e. chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function * current smoking with more than 10 pack-years * previous smoking with more than 10 pack-years * use of systemic steroids 4 weeks (injectable depot steroids 6 weeks) before entry into the baseline period, or more than 2 times * pregnancy * intention to become pregnant during the course of the study * breast feeding * lack of safe contraception

Keywords: asthma ciclesonide fluticasone propionate